抗流感药物“玛巴洛沙韦”耐药性如何？张文宏团队发布研究

Core Viewpoint - A recent study conducted by a team from Fudan University’s Huashan Hospital assessed the sensitivity of the antiviral drug "Marbofloxacin" against influenza viruses in nearly 4,000 Chinese patients, revealing a very low mutation rate associated with drug resistance, thus confirming the drug's effectiveness and safety in clinical applications in China [1][2]. Group 1: Study Findings - The overall detection rate of known mutations related to reduced sensitivity to Marbofloxacin in mainland China is only 0.05% [1]. - The hallmark resistance mutation I38T, previously reported globally, was not detected in this study, indicating that it does not have a competitive advantage in natural transmission due to its significantly reduced viral adaptability [1][2]. - The study identified only one new mutation, PA-D27G, in the H1N1pdm09 virus, with a very low prevalence of 0.32%, which decreases sensitivity to Marbofloxacin by approximately 12.4 times, significantly lower than the typical I38T mutation [2][4]. Group 2: Implications and Future Research - The low prevalence of the D27G mutation, both in China (0.32%) and globally (below 0.1%), suggests that such mutations face adaptive constraints in natural transmission and are unlikely to become mainstream strains [4]. - The study's findings support the notion that flu virus mutations occur randomly and are not directly influenced by the age of patients, with no evidence suggesting that children using Marbofloxacin are at a higher risk of inducing viral mutations [4][5]. - The research team plans to continue monitoring known resistance points and utilize advanced research methods and big data to predict unknown mutations, emphasizing the importance of early detection and treatment in managing viral changes [5].